Recent Non-neurogenic Overactive Bladder Trials
- 15 Downloads
Purpose of Review
We sought to address the most important trials regarding overactive bladder (OAB) syndrome published in the past 5 years regarding pharmacological treatment and minimally invasive procedures (botulinum toxin A, percutaneous tibial nerve stimulation, and sacral neuromodulation).
Most of the randomized controlled trials related to OAB are studying anticholinergics and/or beta-adrenergics versus each other or to a placebo-comparator group. Studies have shown stability of using mirabegron and that combination therapy (anticholinergics plus beta-adrenoceptors) seems a good choice for patients with OAB. Percutaneous tibial nerve stimulation needs further studies with comparators to confirm its role. Regarding intra-vesical botulinic toxin or sacral neuromodulation for OAB, both options present good percentages of patient improvement, with no clinically significant difference between them to this moment.
Despite a growing number of high-quality randomized trials on OAB, further studies are needed comparing different lines of treatment for this disease.
KeywordsOveractive bladder Randomized controlled trials Treatment Review
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130–40.Google Scholar
- 6.Rai BP, Cody JP, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12:CD003193.Google Scholar
- 9.• Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7. This study has stimulated the discussion for further investigation about the association between anticholinergics and dementia. CrossRefGoogle Scholar
- 11.• White WB, Siddiqui E, Tat T, Franks B, Schermer CR. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens. 2018;S1933-1711(18):30241–9. https://doi.org/10.1016/j.jash.2018.08.001 This study shows a stable cardiovascular profile of mirabegron. Google Scholar
- 12.• Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74:324–33. This review is interesting for the network meta-analysis format and because it compares different arms of treatment. CrossRefGoogle Scholar
- 13.Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67:577–88.CrossRefGoogle Scholar
- 14.Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomized double-blind multicenter phase 3b study (BESIDE). Eur Urol. 2016;70(1):136–45.CrossRefGoogle Scholar
- 15.•• Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;1220(4):562–75. This is the largest RCT sampling comparing combined therapy versus monotherapy in OAB treatment. CrossRefGoogle Scholar
- 16.Batista JE, Kolbl H, Herschorn S, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015;7:167–79.CrossRefGoogle Scholar
- 17.Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, et al. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU Int. 2014;114:418–26.Google Scholar
- 18.Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313–20.CrossRefGoogle Scholar
- 20.Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34:685–92.CrossRefGoogle Scholar
- 25.Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Int Braz J Urol. 2018;44(1):10–108.CrossRefGoogle Scholar
- 26.Scaldazza CV, Morosetti C, Giampieretti R, Lonrezetti R, Baroni M. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol. 2017;43(1):121–6.CrossRefGoogle Scholar
- 29.• Chughtai B, Dunphy C, Lee R, et al. Randomized, double-blind, placebo-controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. Can J Urol. 2014;21:7217–21. This is one of the few, well-designed studies comparing botulinum toxin in men with BPH. Google Scholar
- 31.Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomized, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.CrossRefGoogle Scholar
- 34.Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30.CrossRefGoogle Scholar